Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S.

Slides:



Advertisements
Similar presentations
Inadequacies in the Federal Regulation of Agricultural Biotechnology Gregory Jaffe Director, Biotechnology Project Center for Science in the Public Interest.
Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Summary of NEPA and SEPA Coastal Engineering and Land Use Issues in North Carolina Greenville, NC January 13, 2009 Sean M. Sullivan.
Overview of Significant Issues and Identified Alternatives for Draft Environmental Impact Statement: Produce Safety Rule Michael Mahovic, Ph.D. Produce.
Environmental Assessments Human and Animal Drugs Nancy Sager Center for Drug Evaluation and Research Food and Drug Administration.
Phenotypic Characterization Harlan Howard, PhD. Describes the animal, construct, and proposed claim Are there sequences that are likely to contain potential.
Introduction to Regulatory Affairs: Agencies and Permit Process Advanced Biotechnology (c)(8)(A)
U.S. Fish and Wildlife Service Ecological Services Utah Field Office.
Module 3 Counterpart Regulations Standards of Review for Determining Project Effects.
Health Aspect of Disaster Risk Assessment Dr AA Abubakar Department of Community Medicine Ahmadu Bello University Zaria Nigeria.
Molecular Biology. It’s a Matter of Perspective The investigators who submit IBC protocols want to perform their experiments safely. The investigators.
Food Safety Assessment Kevin Greenlees, PhD, DABT Kathleen Jones, PhD.
BIOSAFETY CONCERNS IN THE CONTEXT OF BIOTECHNOLOGY. Presentation for Training Workshop for Regional Advisors Bangkok, Thailand May 2006.
Jeff Jones, DVM, PhD Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of Genetically.
Environmental Safety Assessment Eric Silberhorn, PhD, DABT.
FDA’s Policy for Evaluating Bioengineered Foods Jeanette Glover Glew Food and Drug Administration Center For Food Safety and Applied Nutrition September,
Background, Introduction, Statutory Authority, Introduction to Risk-Based Approach Larisa Rudenko, PhD, DABT.
INADs and Beginning the Review Process Larisa Rudenko, PhD, DABT.
Malini M. Wileman, PhD, RAC Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Regulation of.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
The National Environmental Policy Act (NEPA)
Durability Joseph W. (Jay) Cormier, PhD. Describes the animal, construct, and proposed claim Are there sequences that are likely to contain potential.
Pest Risk Analysis International Plant Protection Convention (IPPC)
Biosafety and recombinant DNA technology. Involves.... Experiments involving the construction or use of GMOs should be conducted after performing a biosafety.
AquaAdvantage Salmon Lisa Danielson. Outline Introduction Explanations Significance Research Question Methodology My approach Literature Review Problems.
EMS / NEPA Integration at the Idaho National Laboratory Bruce Angle & John Irving Battelle Energy Alliance Idaho National Laboratory Environmental Management.
Principles for the Oversight of Synthetic Biology- Precautionary Principle 1  “When an activity raises threats of harm to human health or the environment,
Environmental Assessment for Pharmaceuticals Charles Eirkson, Center for Veterinary Medicine Keith Webber, Ph.D., Center for Drug Evaluation and Research.
HABITAT CONSERVATION PLANNING Charles J. Randel, 1 III, Howard O. Clark, Jr., 2 Darren P. Newman, 2 and Thomas P. Dixon 3 1 Randel Wildlife Consulting,
Data Requirements for Field Release and Monitoring Jon Knight Imperial College London
Risk assessment: Bt corn MON810 Risk assessment: identifying and evaluating possible dangers predicting the chances the danger will occur assessing the.
RISK ASSESSMENT OF GMOs UNDER CONTAINED AND FIELD USE EXPERIMENTS Veronica O. Sinohin; Senior Science Research Specialist Ecosystems Research and Development.
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
USDA-APHIS Plant Pest Risk Assessments Science Issues and Research Needs Biotechnology Risk Assessment Grants Program 2015 Project Director’s Meeting.
USAID Environmental Procedures. EA Training Course Tellus Institute 2 USAID Procedures Overview  USAID environmental review requirements are:  A specific.
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
Completing the NEPA Process for CatEx Projects: Part 3 to CE Closeout.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Chapter 5 Characterizing Genetic Diversity: Quantitative Variation Quantitative (metric or polygenic) characters of Most concern to conservation biology.
ntents/data1/img4/mantis.jpg.
Overview of the USDA Biotechnology Risk Assessment Grants Program Deb Hamernik, PhD National Program Leader, Animal Physiology US Department of Agriculture.
Section 4.0 Human Activity Affects Biological Diversity.
U N I T E D S T A T E S D E P A R T M E N T O F C O M M E R C E N A T I O N A L O C E A N I C A N D A T M O S P H E R I C A D M I N I S T R A T I O N State.
Characterization, Inventory and Monitoring of trends in indigenous livestock Dr. E. D. Ilatsia D. N. Kamiti 23-Oct-15Animal Breeding and Genomics Group1.
Codex Science-based Approach to the Safety of Foods Derived from Modern Biotechnology James H. Maryanski, Ph.D. Food and Drug Administration Center for.
Hazard and Risk Assessment
Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S.
CHAPTER 4 ALTERNATIVES. --- “The driving impetus for conducting environmental impact studies is to comparatively present the effects of proposed alternatives.
NRC Environmental Reviews for Uranium Recovery Applicants and Licensees James Park (301)
Genetically Modified Foods Beth Roberson November 19, 2004 FST 490.
Driving forces Pressure Human travelTrade of commodities State Release the environmentEscape in the environment Contaminant in commodity Stowaway in transport.
Session VII WEIGHING IN ON MICROBIOLOGICAL ADI: EXPERIENCES AND PERSPECTIVES Introduction October 26, 2012.
Quarantine and Movement Control Movement Control, Permitting, and Personnel Adapted from the FAD PReP/NAHEMS Guidelines: Quarantine and Movement Control.
Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern Qualitative Antimicrobial.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
CE 360Dr SaMeH1 Environmental Eng. 1 (CE 360) Associate Professor of Environmental Eng. Civil Engineering Department Engineering College Majma’ah University.
It’s a food… It’s a drug… It’s AquAdvantage Salmon! Ricardo Carvajal Hyman, Phelps & McNamara, P.C st Annual Tulane.
Overview of FDA’s Program for Reviewing New Food Contact Substances
Biosafety and Recombinant DNA Technology
Trade and Pest Management
National Environmental Policy Act (NEPA)
Unit 6 NEPA.
Factors that Affect the Process of Evolution
Introduction to Evolution
Diversity of Life Species Gene pool.
Environmental Requirements and planning grants
FDA Regulation of Animal Biotechnology Products
Presentation transcript:

Environmental Assessment of Genetically Engineered Animals at CVM (FDA) Animal Biotechnology Interdisciplinary Group Center for Veterinary Medicine U.S. Food and Drug Administration Evgenij A. Evdokimov, PhD Erik M. Silberhorn, PhD

Major Statutes Governing Regulation of GE Animals Federal Food, Drug, and Cosmetic Act (FD&C Act) Products are regulated; not processes National Environmental Policy Act (NEPA) Procedural; orders agencies to evaluate impacts of “agency actions”

Guidance for Industry 187* Covers all types of GE animals Definition of “article” rDNA construct intended to affect the structure or function of the animal All GE animals in a lineage are covered Event-based, case-by-case evaluation Enforcement discretion and approval paths New Animal Drug Application (NADA) means mandatory approval prior to marketing Post-market surveillance * eredAnimals/default.htm

Statutory/Regulatory Requirements Sponsor must submit Environmental Assessment/supporting data under INAD/NADA National Environmental Policy Act (NEPA) requirement triggered by “agency action” EA  FONSI? (finding of no significant impact) If no FONSI, EIS (environmental impact statement)

Finding of No Significant Impact (FONSI) NEPA Process Overview Regulated Article Categorical Exclusion May Significantly Affect Meets Criteria Environmental Impact Statement (EIS) No Significant Effects Record of Decision (ROD) Environmental Assessment (EA)

Are there significant direct or indirect effects from introduction of the GE animal into the environment? Basis for satisfying NEPA requirements. Hierarchical Risk-Based Evaluation

Direct and Indirect Effects Pathogen / disease transfer Genetic disturbance Resource competition Displacement Habitat destruction Predation Population changes Community/Ecosystem disruptions

Environmental Assessment: General Risk Questions For a specific GE animal (population) containing a specific rDNA construct…. Likelihood of escape? Containment/redundancy Likelihood of survival if escape occurs? Likelihood of establishment and reproduction? Potential consequences/effects associated with escape? Considered in context of appropriate comparator on a case-by-case basis

Biological Containment Physical Containment Source(s) Escape or Introduction Able to Survive Impact on Target Resources in the Environment (habitats, wildlife) Dispersion Direct and Indirect Effects Accessible Environments Able to Reproduce Establishment Spread of Transgene(s) Wild Conspecifics Feral Relatives Net Fitness Geographical/ Geophysical Containment Conceptual Framework for Environmental Assessment

Consequences of Introduction, Escape, and Dispersion Will depend largely on: Specific physical locations of production or release Extent of containment (if applicable) Physical/mechanical Biological (e.g., sterility, monosex) Geographical/geophysical (environmental conditions) Domestication of species (ability to become feral) Mobility of species “Net fitness”

Fitness* Genetic contribution by an individual’s descendants to future generations of a population Fitness depends on both survival and reproduction Net fitness components include Juvenile and adult viability Age at sexual maturity Female fecundity/male fertility/mating success * These characteristics are used to assess fitness regardless of an animal’s GE status

Definitions, Relationships, Standards Harm ≡ an adverse outcome Hazard ≡ substance or activity that has the potential to cause a harm Risk ≡ conditional probability of an adverse outcome provided that exposure to a receptor has occurred …or Risk  f outcome (exposure, hazard), or “the likelihood of harm” Receptor ≡ individual or population experiencing risk Safety ….reasonable certainty of no harm (established standard)

Potential Environmental Hazards and Risks HazardRisk Use of viral sequences, including vectors (Characterized in Molecular Characterization steps) Increased probability of new pathogenic recombinants Traits increasing species fitness or adaptation (Characterized in Phenotypic Characterization) Increased probability of disruption of existing ecosystems due to establishment of a GE animal in the environment Altered population dynamics due to horizontal transfer of gene construct(s) (Likelihood of transfer part of Molecular Characterization steps) Specific risk is a function of the nature of the trait

Areas of interest Containment effectiveness and ways to ensure containment of GE animals Physical/mechanical Biological (e.g., sterility, monosex) Geographical/geophysical (environmental conditions) Fitness Case by case evaluation of GE animals

Areas of interest Biological containment Control of released GE animals or invasive species Commercial production

Questions? Contacts at CVM: Dr. Eric Silberhorn Dr. Evgenij Evdokimov